The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011 · cited 1×
“0 [13], a cranial magnetic resonance imaging (MRI) scan demonstrating lesions consistent with MS and at least 1 medically documented relapse within 12 months prior to randomization.”
BackgroundMcDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969 · cited 1×
“All patients in both studies provided written informed consent and had a diagnosis of MS according to McDonald criteria [12], a baseline Expanded Disability Status Scale (EDSS) score of 0.”
MethodSelf-citationA Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386 · cited 5×
“For the overall AFFIRM study population, the cumulative probability of 12-week sustained disability progression at 2 years was 17 % in the natalizumab group compared with 29 % in the placebo group, representing a 42 % reduction in the risk of sustained disability progression with natalizumab treatment (HR = 0.58; CI:…”
BackgroundMethodInfluentialSelf-citationIntramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450 · cited 1×
“In patients treated with IFNβ or glatiramer acetate, 62 %–68 % will experience relapses and 20 %–27 % will worsen by ≥ 1 point on the EDSS scale within 2 years [26–29].”
BackgroundSelf-citationThe IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Elices, M. J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M. E., & Lobb, R. R. (1990) · Cell · doi:10.1016/0092-8674(90)90661-w · Cited by 1,808 · cited 1×
“Binding between these cell types is the result of interactions between the adhesion molecule α4β1 integrin on the surface of leukocytes and vascular cell adhesion molecule (VCAM)-1 present on the surface of endothelial cells [2–4].”
BackgroundPrevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737 · cited 1×
“Natalizumab has been shown to reduce the transmigration of lymphocytes into the CNS and to prevent the development of experimental autoimmune encephalomyelitis in animal studies [ 5 ].”
BackgroundStatistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“The presentation conforms to recently published guidelines on reporting subgroup analyses [18].”
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344 · cited 5×
“001) over 2 years compared with IFNβ-1a alone [10].”
BackgroundMethodResultInfluentialSelf-citationA Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242 · cited 1×
“Previously, a post hoc analysis of data from a phase 2 study of natalizumab in patients with relapsing MS showed the agent to have the greatest effect in patients with more disease activity [ 6 , 22].”
Self-citationGirard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Self-citationA longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861 · cited 1×
“Indicators of more active disease early in the clinical course, such as frequent relapses, high T2-lesion load and the presence of Gd+ lesions, have been correlated with a higher risk of disability progression later in the clinical course [15, 16, 21].”
BackgroundSelf-citationBaron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G., & Janeway, C. A. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.1.57 · Cited by 835 · cited 1×
“Binding between these cell types is the result of interactions between the adhesion molecule α4β1 integrin on the surface of leukocytes and vascular cell adhesion molecule (VCAM)-1 present on the surface of endothelial cells [2–4].”
BackgroundWEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Carlos, T., Schwartz, B., Kovach, N., Yee, E., Rosa, M., Osborn, L., Chi-Rosso, G., Newman, B., Lobb, R., & Rosso M$[corrected to Rosa, M. (1990) · Blood · doi:10.1182/blood.v76.5.965.965 · Cited by 527
Axonal pathology in multiple sclerosis: relationship to neurologic disability
Trapp, B. D., Ransohoff, R., & Rudick, R. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199906000-00008 · Cited by 475 · cited 1×
“There has been a shift in recent years toward early treatment with disease-modifying therapies to reduce the effects of recurrent inflammation and axonal injury, thereby achieving better outcomes [24, 25].”
BackgroundSelf-citationThe effect of anti-α4 integrin antibody on brain lesion activity in MS
Tubridy, N., Behan, P. O., Capildeo, R., Chaudhuri, A., Forbes, R., Hawkins, C. P., Hughes, R. A. C., Palace, J., Sharrack, B., Swingler, R., et al. (1999) · Neurology · doi:10.1212/wnl.53.3.466 · Cited by 307
Self-citationPathogenesis of multiple sclerosis
ffrench-Constant, C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91118-5 · Cited by 226 · cited 1×
“Inflammation, a pathologic hallmark of MS, results from infiltration of the central nervous system (CNS) by leukocytes [1], which gain access to the CNS by adhering to blood-brain barrier endothelial and glial cells.”
BackgroundNatural history of secondary-progressive multiple sclerosis
Tremlett, H., Zhao, Y., & Devonshire, V. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507084264 · Cited by 217 · cited 1×
“Natural history data suggest that the median time from the onset of relapsing MS to secondary progressive MS is approximately 19 years [ 19 ].”
BackgroundRío, J., Porcel, J., Téllez, N., Sánchez-Betancourt, A., Tintoré, M. A., Arévalo, M. J., Nos, C., & Montalban, X. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1173oa · Cited by 188 · cited 1×
“In addition, discontinuation of IFNβ or glatiramer acetate due to side effects or perceived treatment failure is a problem in 14 % of patients with relapsing MS in the first few years of therapy [ 30 , 31].”
BackgroundRandomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects
O’Connor, P. W., Goodman, A., Willmer-Hulme, A. J., Libonati, M. A., Metz, L., Murray, R. S., Sheremata, W. A., Vollmer, T. L., Stone, L. A., & the Natalizumab Multiple Sclerosis Trial Group (2004) · Neurology · doi:10.1212/01.wnl.0000128136.79044.d6 · Cited by 167 · cited 1×
“Following favorable phase 2 studies [6–8], a randomized, doubleblind, placebo-controlled phase 3 study of natalizumab monotherapy in relapsing-remitting MS (AFFIRM) demonstrated a reduction of sustained disability progression by 42 % (p < 0.”
BackgroundSelf-citationStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
O’Rourke, K., & Hutchinson, M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1131oa · Cited by 143 · cited 1×
“In addition, discontinuation of IFNβ or glatiramer acetate due to side effects or perceived treatment failure is a problem in 14 % of patients with relapsing MS in the first few years of therapy [30, 31].”
BackgroundSelf-citationShort-term prognosis in early relapsing-remitting multiple sclerosis
Scott, T. F. M., Schramke, C. J., Novero, J., & Chieffe, C. (2000) · Neurology · doi:10.1212/wnl.55.5.689 · Cited by 56 · cited 1×
“5 sustained for at least 1 year [14, 20].”
BackgroundRelapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
O'Connor, P. W., Miller, D. H., Riester, K. A., Yang, M., Panzara, M. A., Dalton, C. M., Miszkiel, K., Khan, O., Rice, G. P., Sheremata, W. A., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1205oa · Cited by 48 · cited 1×
“Previously, a post hoc analysis of data from a phase 2 study of natalizumab in patients with relapsing MS showed the agent to have the greatest effect in patients with more disease activity [6, 22].”
BackgroundSelf-citationLosseff, N. A., Miller, D. H., Kidd, D. P., & Thompson, A. J. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700105 · Cited by 31 · cited 1×
“Indicators of more active disease early in the clinical course, such as frequent relapses, high T2-lesion load and the presence of Gd+ lesions, have been correlated with a higher risk of disability progression later in the clinical course [ 15 , 16, 21].”
BackgroundSelf-citationEarly intervention with immunomodulatory agents in the treatment of multiple sclerosis
Jeffery, D. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00039-4 · Cited by 26 · cited 1×
“There has been a shift in recent years toward early treatment with disease-modifying therapies to reduce the effects of recurrent inflammation and axonal injury, thereby achieving better outcomes [24, 25].”
BackgroundScott, T. F. M., Schramke, C. J., & Cutter, G. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms910oa · Cited by 5 · cited 1×
“5 sustained for at least 1 year [14, 20].”
BackgroundDiagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2 · cited 1×
“Evidence exists that MS is a pathologically heterogeneous disease [11], meaning patients may respond differently to treatment.”
Background
Cited by
Rae-Grant, A., Day, G. S., Marrie, R. A., Rabinstein, A., Cree, B. A. C., Gronseth, G. S., Haboubi, M., Halper, J., Hosey, J. P., Jones, D. E., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005347 · Cited by 595
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M., & Bielekova, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00577 · Cited by 310
Kappos, L., Bates, D., Edan, G., Eraksoy, M., Garcia-Merino, A., Grigoriadis, N., Hartung, H.-P., Havrdová, E., Hillert, J., Hohlfeld, R., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70149-1 · Cited by 262
Self-citationGiovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., & Greenberg, S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70023-0 · Cited by 252
Self-citation
Metadata
- Authors
- for the AFFIRM and SENTINEL Investigators, Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., O’Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E.-W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., & Panzara, M. A.
- Venue
- Journal of Neurology
- Published
- 2009-03
- Volume
- 256
- Issue
- 3
- Pages
- 405-415
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2127001605
- Cited by
- 234
- References
- 34
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.